Congenital cytomegalovirus infection (cCMV) is the most common congenital viral infection, with a consistent rate of morbidity, mortality, and long-term sequelae, especially in the case of late diagnosis. Nevertheless, a universal screening for CMV is not currently recommended, and global awareness about this infection, as well as accurate and shared indications on follow-up and treatment, are still lacking. We reviewed data about 59 suspect cCMV cases who referred to our center from 2014 to 2021. We report 41 cases of confirmed cCMV diagnosed at birth, with clinical or radiological abnormalities in 36.6% of them. Other five patients received a late diagnosis and all presented neurological impairment. Twelve patients received therapy with Valganciclovir within the first month of life, with favorable outcome in nine cases. Therapy after the first month of life was attempted in four patients, with improvement in one case. The overall awareness about cCMV infection was 32.6%. Considering our population, maternal serological screening followed by targeted testing of neonates could be an effective strategy. Some aspects of cCMV infection management should be further investigated, such as indication of treatment after the first month of life or in asymptomatic patients. Awareness about the infection should be improved to implement preventive strategies.

Congenital CMV, Lights and Shadows on Its Management: The Experience of a Reference Center in Northern Italy / V. Rubinacci, M. Fumagalli, G. Meraviglia, L. Gianolio, A. Sala, M. Stracuzzi, A. Dighera, G.V. Zuccotti, V. Giacomet. - In: CHILDREN. - ISSN 2227-9067. - 9:5(2022 May 03), pp. 655.1-655.8. [10.3390/children9050655]

Congenital CMV, Lights and Shadows on Its Management: The Experience of a Reference Center in Northern Italy

V. Rubinacci
Primo
;
M. Fumagalli
Secondo
;
L. Gianolio;M. Stracuzzi;A. Dighera;G.V. Zuccotti
Penultimo
;
V. Giacomet
Ultimo
2022

Abstract

Congenital cytomegalovirus infection (cCMV) is the most common congenital viral infection, with a consistent rate of morbidity, mortality, and long-term sequelae, especially in the case of late diagnosis. Nevertheless, a universal screening for CMV is not currently recommended, and global awareness about this infection, as well as accurate and shared indications on follow-up and treatment, are still lacking. We reviewed data about 59 suspect cCMV cases who referred to our center from 2014 to 2021. We report 41 cases of confirmed cCMV diagnosed at birth, with clinical or radiological abnormalities in 36.6% of them. Other five patients received a late diagnosis and all presented neurological impairment. Twelve patients received therapy with Valganciclovir within the first month of life, with favorable outcome in nine cases. Therapy after the first month of life was attempted in four patients, with improvement in one case. The overall awareness about cCMV infection was 32.6%. Considering our population, maternal serological screening followed by targeted testing of neonates could be an effective strategy. Some aspects of cCMV infection management should be further investigated, such as indication of treatment after the first month of life or in asymptomatic patients. Awareness about the infection should be improved to implement preventive strategies.
TORCH4; congenital CMV2; cytomegalovirus (CMV)1; sensorineural hearing loss (SNHL)5; valganciclovir3
Settore MED/38 - Pediatria Generale e Specialistica
3-mag-2022
Article (author)
File in questo prodotto:
File Dimensione Formato  
children-09-00655.pdf

accesso aperto

Descrizione: Article
Tipologia: Publisher's version/PDF
Dimensione 233 kB
Formato Adobe PDF
233 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/951053
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 3
social impact